NCT03421353 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03421353
Title	AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	AstraZeneca
Indications	Advanced Solid Tumor
Therapies	Cisplatin + Danvatirsen + Durvalumab + Gemcitabine Carboplatin + Danvatirsen + Durvalumab + Gemcitabine Cisplatin + Danvatirsen + Durvalumab + Fluorouracil Danvatirsen + Durvalumab Carboplatin + Danvatirsen + Durvalumab + Nab-paclitaxel
Age Groups:	adult \| senior
Covered Countries	USA

Facility	City	State	Zip	Country	Details
Research Site	Lafayette	Indiana	47905	United States	Details
Research Site	Oklahoma City	Oklahoma	73104	United States	Details
Research Site	Nashville	Tennessee	37203	United States	Details
Research Site	Dallas	Texas	75230	United States	Details
Research Site	Houston	Texas	77030	United States	Details
Research Site	Fairfax	Virginia	22031	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03421353Clinical Trial Detail